GeneHealth - Your precision medicine

Glycogen Storage Disease Vii

Disease Details

Family Health Simplified

Buy Membership

Description: Glycogen storage disease VII, also known as Tarui’s disease, is a rare metabolic disorder where the body lacks the enzyme phosphofructokinase, leading to an inability to properly break down glycogen in muscle cells.
Type: Glycogen storage disease VII (GSD VII) is also known as Tarui's disease. It is inherited in an autosomal recessive manner.
Signs And Symptoms: Glycogen Storage Disease Type VII (GSD VII), also known as Tarui's disease, primarily affects muscle function. Signs and symptoms include:

- Muscle weakness and cramps, especially during exercise
- Myoglobinuria (presence of myoglobin in the urine), leading to dark-colored urine after exercise
- Fatigue and general exercise intolerance
- Hemolytic anemia, which may cause jaundice, pallor, and fatigue

These symptoms are due to a deficiency in the enzyme phosphofructokinase, which impairs the muscle cells' ability to break down glycogen into glucose for energy.
Prognosis: Glycogen Storage Disease Type VII (GSD VII), also known as Tarui's disease, is a rare inherited disorder characterized by a deficiency of the muscle enzyme phosphofructokinase (PFK). This enzyme deficiency impairs the body's ability to convert glycogen into glucose, which is essential for energy production in muscles.

Prognosis:
The prognosis of GSD VII varies depending on the severity of the condition. Some individuals may experience mild symptoms and maintain a relatively normal life with appropriate management, including dietary modifications and avoiding strenuous exercise. However, more severe cases can lead to significant muscle weakness, exercise intolerance, and potential complications such as myoglobinuria, which can affect kidney function. The variability in the presentation makes it important for each patient to have a tailored management plan under the care of healthcare professionals familiar with metabolic disorders.
Onset: Glycogen Storage Disease VII (GSD VII), also known as Tarui's disease, typically has an onset in early childhood, although it can also present later in life.
Prevalence: The prevalence of Glycogen Storage Disease Type VII (GSD VII), also known as Tarui disease, is considered to be very rare, but specific numerical data on prevalence aren't well-established due to its rarity. Fewer than 100 cases have been reported in the medical literature worldwide.
Epidemiology: Glycogen Storage Disease VII (GSD VII), also known as Tarui's disease, is a rare inherited metabolic disorder. The exact prevalence is unclear, but it is considered extremely rare, with few hundred cases reported worldwide. It typically presents in childhood or early adulthood and affects both sexes equally. The condition is caused by mutations in the PFKM gene, which encodes the muscle isoform of the enzyme phosphofructokinase.
Intractability: Glycogen Storage Disease Type VII (GSD VII), also known as Tarui's disease, is generally intractable. There is no cure, and management focuses on symptomatic treatment and lifestyle adjustments to mitigate symptoms. Regular monitoring and supportive care can help improve the quality of life, but the disease cannot be eradicated.
Disease Severity: Glycogen Storage Disease VII (GSD VII), also known as Tarui's disease, can vary in severity. The disease affects muscle function and often results in exercise intolerance, muscle cramps, and myoglobinuria (presence of myoglobin in urine) after strenuous activity. Severe cases can present with symptoms during childhood, while milder forms might only cause issues during intense physical activity. In some cases, there may be associated symptoms like hemolytic anemia. The severity largely depends on the specific mutation in the gene encoding the enzyme phosphofructokinase and the residual enzyme activity.
Healthcare Professionals: Disease Ontology ID - DOID:11721
Pathophysiology: Glycogen Storage Disease VII (GSD VII), also known as Tarui disease, is a rare inherited metabolic disorder characterized by a deficiency in the enzyme phosphofructokinase (PFK). This enzyme is critical for the glycolytic pathway, which is necessary for the conversion of glucose to energy in muscle cells. The deficiency impairs the ability of muscles to break down glycogen for energy, leading to an accumulation of glycogen in muscle tissues.

The pathophysiology involves the following key aspects:
1. Enzyme Deficiency: Mutations in the PFKM gene, which encodes the muscle isoform of phosphofructokinase, reduce or eliminate enzyme activity.
2. Impaired Glycolysis: Reduced or absent PFK activity disrupts glycolysis, causing an energy deficit in muscle cells during exercise or stress.
3. Glycogen Accumulation: Inability to effectively convert glycogen to glucose leads to its build-up in muscle tissues, contributing to muscle weakness and cramping.

Clinical manifestations of GSD VII often include exercise intolerance, muscle cramps, myoglobinuria (presence of myoglobin in urine, indicating muscle breakdown), and in some cases, hemolytic anemia. Treatment typically focuses on managing symptoms and may include dietary modifications and avoidance of strenuous exercise.
Carrier Status: Glycogen Storage Disease VII (GSD VII), also known as Tarui disease, is inherited in an autosomal recessive manner. This means a person needs to inherit two copies of the mutated gene, one from each parent, to be affected by the disease. Carriers, who have only one copy of the mutated gene, typically do not show symptoms.
Mechanism: Glycogen Storage Disease VII (GSD VII), also known as Tarui disease, is caused by mutations in the PFKM gene, which encodes the muscle isoform of the enzyme phosphofructokinase (PFK).

**Mechanism:**
The primary defect in GSD VII is the deficient or impaired activity of the PFK enzyme in muscle tissue. PFK is a key enzyme in the glycolytic pathway, responsible for converting fructose-6-phosphate to fructose-1,6-bisphosphate, a crucial step in the metabolism of glucose to produce energy.

**Molecular Mechanisms:**
1. **Enzyme Deficiency:** Mutations in the PFKM gene lead to a reduced quantity or function of the PFK enzyme in muscle cells.
2. **Glycolytic Block:** Due to inadequate PFK activity, glycolysis is impaired, leading to a buildup of upstream metabolites such as glucose-6-phosphate and fructose-6-phosphate.
3. **Glycogen Accumulation:** The impaired glycolytic flux results in decreased ATP production and a compensatory increase in glycogen synthesis, causing glycogen accumulation in muscle cells.
4. **Energy Deficit:** During exercise or physical activity, the inability to effectively convert glucose to energy manifests as muscle cramping, weakness, and fatigue due to the energy deficit.

Overall, the molecular consequences of PFKM gene mutations in GSD VII disrupt normal glucose metabolism and energy production in muscles, leading to the characteristic symptoms of the disease.
Treatment: Glycogen Storage Disease VII, also known as Tarui's disease, is a rare genetic disorder that affects muscle metabolism. Treatment primarily focuses on managing symptoms and preventing complications. This may include:

1. Dietary modifications: A high-protein, low-carbohydrate diet can help manage symptoms by reducing the reliance on glycogen for energy.
2. Avoiding strenuous exercise: Minimizing intense physical activity can help prevent muscle pain and cramping.
3. Medications: In some cases, medications like beta-blockers may be prescribed to help alleviate muscle symptoms.
4. Physical therapy: To help maintain muscle strength and function without triggering symptoms.

Currently, there is no cure for Glycogen Storage Disease VII, so treatment strategies aim to improve quality of life and manage symptoms.
Compassionate Use Treatment: Glycogen Storage Disease Type VII (GSD VII), also known as Tarui's disease, is a rare metabolic disorder. Currently, there are no established compassionate use treatments specifically approved for GSD VII. However, off-label or experimental treatments may include the following:

1. **Dietary Management**: Low-carbohydrate, high-protein diets may help manage symptoms by minimizing the reliance on glycogen breakdown for energy.

2. **Ketogenic Diet**: This high-fat, low-carbohydrate diet can help shift the body's primary energy source from carbohydrates to fats, potentially alleviating muscle pain and weakness.

3. **Gene Therapy**: Experimental gene therapy is being researched to correct the underlying genetic defect by introducing a functional gene to replace the defective one. However, this is still in the early stages of research.

4. **Enzyme Replacement Therapy (ERT)**: Although not yet available for GSD VII, ERT is being explored as a potential treatment option in clinical trials.

5. **Pharmacological Agents**: Some studies are investigating the use of drugs that can modify metabolic pathways, although these are largely experimental.

Consultation with a medical professional specializing in metabolic disorders is crucial for exploring these and other potential treatments.
Lifestyle Recommendations: Glycogen Storage Disease Type VII (GSD VII), also known as Tarui's disease, is a rare inherited metabolic disorder. It primarily affects the muscles and red blood cells and leads to exercise intolerance, muscle pain, and muscle cramps. Here are some lifestyle recommendations for individuals with GSD VII:

1. **Dietary Management**: A high-protein, low-carbohydrate diet may help to manage symptoms. Frequent, smaller meals can help maintain blood sugar levels. Avoiding foods high in carbohydrates is essential to prevent muscle cramps and fatigue.

2. **Moderate Exercise**: While strenuous exercise should be avoided due to muscle pain and cramps, light to moderate exercise might be beneficial. Activities such as walking or light cycling can help maintain muscle tone without overexertion.

3. **Regular Monitoring**: Regular follow-ups with a healthcare provider are crucial to monitor the disease's progression and manage symptoms effectively.

4. **Hydration**: Maintaining good hydration is important as dehydration can exacerbate muscle cramps and fatigue.

5. **Managing Pain**: Non-pharmacological methods like physical therapy, massage, and gentle stretching exercises can alleviate muscle pain and discomfort.

6. **Emergency Planning**: It is helpful to have an emergency plan in place, including an identification bracelet indicating the metabolic disorder, in case of severe hypoglycemia or other sudden health issues.

7. **Avoiding Triggers**: Avoid factors that can trigger muscle pain and cramps, such as extreme temperatures, stress, and overexertion.

8. **Genetic Counseling**: Families may benefit from genetic counseling to understand the inheritance pattern and recurrence risk.

Consultation with a healthcare provider specializing in metabolic disorders is recommended to tailor these recommendations to the individual's specific needs.
Medication: Glycogen Storage Disease VII (GSD VII), also known as Tarui's disease, does not have a specific pharmacological treatment. Management typically focuses on dietary modifications to reduce symptoms. These may include a high-protein diet and avoiding strenuous exercise to prevent muscle fatigue and cramps. In some cases, supplements like bicarbonate can be considered to help alleviate muscle pain and cramps. Always consult with a healthcare provider for personalized management plans.
Repurposable Drugs: For Glycogen Storage Disease Type VII (GSD VII), also known as Tarui's disease, there is limited information on repurposable drugs specifically targeting this condition. The primary management involves dietary modifications to avoid foods that can exacerbate symptoms and to ensure balanced nutrient intake.

However, potential areas for drug repurposing might involve:
1. Anti-inflammatory agents to manage muscle pain and cramping.
2. Agents used in other metabolic disorders, like glucose-regulating medications.

Further research and clinical trials would be necessary to identify and confirm effective repurposable drugs for GSD VII.
Metabolites: Glycogen Storage Disease VII (GSD VII), also known as Tarui disease, primarily involves the following metabolites:

1. **Elevated Metabolites:**
- **Glycogen:** Accumulates in muscles due to the inability to break it down properly.
- **Fructose-1,6-bisphosphate:** This intermediate in glycolysis can accumulate due to the deficiency of phosphofructokinase.
- **AMP (adenosine monophosphate):** May be elevated due to an increase in ATP breakdown.

2. **Reduced Metabolites:**
- **ATP (adenosine triphosphate):** Decreased in muscle cells due to impaired glycolysis.
- **Lactate:** Often lower than expected post-exercise levels since glycolysis is disrupted.

The impact of these metabolite changes is primarily observed during exercise and muscle activity, leading to muscle cramps and weakness.
Nutraceuticals: Glycogen Storage Disease Type VII, also known as Tarui's disease, is a rare metabolic disorder that affects muscle function due to a deficiency in the enzyme phosphofructokinase. Nutraceuticals are food-derived products that provide health benefits beyond basic nutrition, but there is limited evidence specifically regarding their efficacy in treating Glycogen Storage Disease Type VII. Management typically focuses on dietary modifications to alleviate symptoms. Always consult healthcare professionals for tailored advice.
Peptides: Glycogen Storage Disease VII (GSD VII), also known as Tarui’s disease, is caused by a deficiency of the enzyme phosphofructokinase (PFK). This enzyme deficiency prevents the proper breakdown of glycogen, affecting energy production, especially in muscle cells.

The use of peptides or therapeutics like enzyme replacement therapy is currently under investigation. As for "nan" (likely referring to nanoparticle-based delivery systems), this area of research holds potential for targeted therapies but is not yet a standard treatment for GSD VII.